While Brilinta is currently approved to reduce the rate of adverse cardiovascular events in patients who have previously suffered a heart attack AstraZeneca had hoped to expand its use into new areas. They had also hoped it would be able to add to its coffers with annual sales of more than$3.5 billion within the next 7-years.
“The result in SOCRATES has no bearing whatsoever for the rest of the program,” Elisabeth Bjork, AstraZeneca’s head of medicines development for cardiovascular and metabolic disease told Reuters. “We are still very excited about the potential.” She also stated that they expect to have results from another trial evaluating the medicine in peripheral arterial disease later this year.
According to the National Institutes of Health approximately 795,000 people suffer a stroke in the US each year, with about 160,000 dying from stroke-related causes, making it the 4th leading cause of death in the country.
A stroke, or “brain attack,” occurs when blood circulation to the brain fails, causing cells to die from lack of oxygen. Those caused by a blocked blood vessel in the brain or neck are known as ischemic strokes, and generally stem from the formation of a clot called thrombosis; the movement of a clot from another part of the body such as the heart to the brain, called embolism; or a severe narrowing of an artery in or leading to the brain, called stenosis. Bleeding into the brain or the spaces surrounding the brain causes the second type of stroke, called hemorrhagic stroke.
Warning signs include: Sudden numbness or weakness of face, arm, or leg, especially on one side of the body; Sudden confusion, or trouble talking or understanding speech; Sudden trouble seeing in one or both eyes, as well as double vision; Sudden trouble walking, dizziness, or loss of balance or coordination and sudden severe headache with no discernable cause. Additional symptoms may include drowsiness, nausea and vomiting.